Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA): Insights into Pathogenesis, Diagnosis, and Management

Luis Jesuino de Oliveira Andrade, Gabriela Correia Matos de Oliveira, Luís Matos de Oliveira, Luanna Lopes da Silva Ramos, Osmario Jorge de Mattos Salles

https://doi.org/10.1590/SciELOPreprints.14296

Submitted on: 2025-11-25
Posted on: 2025-12-11 (version 1)
(YYYY-MM-DD)

Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA): Insights into Pathogenesis, Diagnosis, and Management

[1] Luís Jesuino de Oliveira Andrade - https://orcid.org/0000-0002-7714-0330
[2] Gabriela Correia Matos de Oliveira - https://orcid.org/0000-0002-8042-0261
[1] Luís Matos de Oliveira - https://orcid.org/0000-0003-4854-6910
[3] Luanna Lopes da Silva Ramos - https://orcid.org/0009-0002-1499-562X
[4] Osmario Jorge de Mattos Salles - https://orcid.org/0009-0002-1859-0478

[1] Health Department State University of Santa Cruz, Ilhéus, Bahia, Brazil.
[2] José Silveira Foundation, Salvador, Bahia, Brazil.
[3] Faculty of Medicine of UNIFACS – Salvador – Bahia – Brazil.
[4] Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil.

Correspondence
Luís Jesuino de Oliveira Andrade
Universidade Estadual de Santa Cruz - Campus Soane Nazaré de Andrade, Rod. Jorge Amado, Km 16 - Salobrinho, Ilhéus - BA, 45662-900 – Brasil.
E-mail: luis_jesuino@yahoo.com.br

Authors' contributions

LJOA: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Validation, Visualization, Writing – Review & Editing.

GCMO: Data Curation, Formal Analysis, Investigation, Methodology, Supervision, Validation, Visualization. Writing – Original Draft Preparation.

LMO: Data Curation, Formal Analysis, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Validation, Visualization, Writing – Review & Editing.

LLSR: Formal Analysis, Methodology, Validation.

OJMS: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Validation, Visualization, Writing – Review & Editing.

Data statement: The research data is contained within the manuscript itself.

ABSTRACT

Background: Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) represents a unified conceptual framework proposed in 2011 to encompass diverse immune-mediated disorders triggered by adjuvant exposure in genetically predisposed individuals. **Objective:** This review aims to synthesize the current understanding of ASIA's pathogenesis, clinical manifestations, diagnostic approaches, and therapeutic strategies, while identifying critical gaps in existing research. **Methods:** A comprehensive narrative synthesis was conducted, examining literature from multiple databases (PubMed/MEDLINE, Scopus, Web of Science, Embase) for publications spanning from 2011 through 2025. Data were synthesized across four domains: immunopathogenic mechanisms, clinical phenotypes, evolution of diagnostic criteria, and emerging adjuvant substances. **Results**: The pathophysiology of ASIA syndrome is complex, involving innate immune activation, a breakdown of self-tolerance, and chronic inflammation. Primary triggers include aluminum-based vaccine adjuvants, silicone implants, and other biomaterials. Clinically, the syndrome manifests with significant heterogeneity, encompassing constitutional symptoms, musculoskeletal involvement, and multiorgan system pathology. Current diagnostic criteria require further refinement, and therapeutic management primarily emphasizes the removal of the inciting adjuvant and subsequent immunomodulation. Controversial aspects persist, including debates regarding its nosological validity, implications for vaccine safety, and medico-legal dimensions. **Conclusion:** Despite ongoing scientific debate, ASIA represents a valuable framework for understanding the link between adjuvant exposure and autoimmune phenomena. Future research must prioritize prospective cohort studies, advanced immunophenotyping, standardized diagnostic protocols, and the development of safer adjuvants to optimize patient care without compromising public health initiatives.

Keywords: Autoimmune syndrome, Adjuvants, Shoenfeld syndrome, Vaccine safety, Silicone implants.

INTRODUCTION

The recognition of unexplained autoimmune manifestations following exposure to various immunostimulatory substances led Shoenfeld and Agmon-Levin to propose a unifying concept termed Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA), also known as Shoenfeld's syndrome, first described in 2011 [1]. This paradigm emerged from systematic observations of similar clinical presentations across seemingly

distinct conditions, such as Gulf War syndrome, macrophagic myofasciitis, siliconosis, and post-vaccination phenomena [2]. The syndrome encompasses a heterogeneous spectrum of immune-mediated disorders that manifest in genetically susceptible individuals upon exposure to substances possessing adjuvant properties, including aluminum salts, silicone implants, infectious agents, and various biomaterials [3].

Adjuvants initiate a cascade of immunological events that can disrupt immune tolerance, promoting systemic inflammation and autoimmunity in vulnerable hosts. The pathogenesis of ASIA involves a complex interplay between environmental triggers and genetic factors, which explains the variable symptomatology and disease progression observed among patients. Common symptoms include arthralgia, myalgia, chronic fatigue, and neurological disturbances, often overlapping with established autoimmune and inflammatory disorders such as Sjögren's syndrome and undifferentiated connective tissue disease, thereby complicating diagnosis [4].

Initial diagnostic criteria for ASIA required the fulfillment of either two major criteria or one major criterion combined with two minor criteria. Major criteria included documented exposure to an external adjuvant prior to symptom onset, the appearance of characteristic symptoms, clinical improvement following adjuvant removal, and histological evidence consistent with immune activation. Minor criteria encompassed the detection of non-specific autoantibodies, specific human leukocyte antigen (HLA) associations, and progression toward a defined autoimmune disease [5]. However, these diagnostic parameters have generated considerable debate concerning their specificity and the potential for misclassifying well-established autoimmune conditions under the ASIA umbrella.

Contemporary research has expanded the ASIA framework to include emerging adjuvants such as polypropylene meshes, novel vaccine formulations, and cosmetic biomaterials [6]. The COVID-19 pandemic prompted renewed scrutiny of adjuvant-related autoimmune phenomena, with documented cases following both SARS-CoV-2 infection and vaccination [7]. Consequently, research on ASIA continues to evolve, aiming to clarify its immunopathogenesis and improve diagnostic precision. A deeper understanding of ASIA holds promise for advancing vaccine adjuvant safety, refining autoimmune disease classifications, and fostering personalized medical approaches to reduce the burden of adjuvant-induced immune complications [8]. This review synthesizes current knowledge on ASIA's pathogenesis, clinical characteristics, and diagnostic approaches while highlighting critical areas requiring further investigation.

METHODOLOGY

Study Design and Search Strategy

This review employed a narrative synthesis approach to evaluate the current understanding of ASIA. A systematic literature search was conducted across multiple electronic databases, including PubMed/MEDLINE, Scopus, Web of Science, and Embase, covering publications from the syndrome's initial description in 2011 through 2025. The search strategy incorporated Medical Subject Headings (MeSH) terms and free-text keywords such as "ASIA syndrome," "Shoenfeld's syndrome," "autoimmune/inflammatory syndrome induced by adjuvants," "adjuvant-related autoimmunity," "macrophagic myofasciitis," "siliconosis," and "post-vaccination autoimmunity." Boolean operators (AND, OR, NOT) were used to refine queries and enhance retrieval specificity.

Selection Criteria and Study Inclusion

Eligible studies included original research articles, systematic reviews, meta-analyses, case reports, and case series published in peer-reviewed journals. Inclusion criteria required publications addressing the pathophysiological mechanisms, clinical manifestations, diagnostic approaches, or epidemiological aspects of ASIA syndrome. Studies involving human subjects exposed to adjuvant-containing substances, such as aluminum-based vaccine adjuvants, silicone implants, polypropylene meshes, and other biomaterials, were prioritized. Both English and non-English language publications with available translations were considered to minimize language bias.

Exclusion criteria eliminated studies lacking primary data, editorials without substantial empirical content, abstracts without full-text availability, and publications focusing exclusively on non-adjuvant-related autoimmune conditions. Studies with inadequate methodological quality, undefined diagnostic criteria, or insufficient documentation of adjuvant exposure were excluded after quality assessment.

Quality Assessment and Synthesis Framework

Given the heterogeneity of study designs, outcome measures, and clinical presentations within ASIA, a narrative synthesis approach was deemed most appropriate, precluding a quantitative meta-analysis. Data were synthesized thematically across four primary domains: (1) immunopathogenic mechanisms underlying adjuvant-induced autoimmunity; (2) clinical phenotypes and symptomatological patterns; (3) the evolution and validation of diagnostic criteria; and (4) emerging adjuvant substances and contemporary clinical contexts, including post-COVID-19 vaccination phenomena.

The synthesis integrated findings from basic immunology research, clinical observational studies, and epidemiological investigations to construct a comprehensive framework elucidating ASIA's multifactorial etiology. Particular attention was directed toward identifying patterns of genetic predisposition, environmental triggers, and immunological cascades contributing to syndrome manifestation. A comparative analysis of diagnostic criteria proposed by different research groups was performed to evaluate their sensitivity, specificity, and clinical utility.

Identification of Research Gaps and Future Directions

Throughout the synthesis process, critical evaluation identified areas of scientific uncertainty, methodological limitations, and unresolved controversies regarding ASIA's nosological status. These gaps were systematically cataloged to inform recommendations for future investigative priorities, including prospective cohort studies with standardized diagnostic protocols, mechanistic research elucidating molecular pathways of adjuvant-induced immune dysregulation, and validation studies assessing the discriminatory capacity of current diagnostic criteria.

This methodology prioritized transparency in reporting synthesis decisions and acknowledged inherent limitations in synthesizing evidence from heterogeneous sources with varying methodological rigor. This approach ensured a balanced interpretation of existing evidence while recognizing areas requiring additional empirical investigation (Figure 1).

Figure 1. Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)



HISTORICAL CONTEXT AND CONCEPTUAL FRAMEWORK

The recognition of ASIA emerged from disparate clinical observations that converged into a unified paradigm. Gulf War veterans presenting with unexplained multisystem complaints [9], post-vaccination adverse events [2], and recipients of silicone implants developing autoimmune features revealed consistent patterns of adjuvant-triggered immune dysregulation [10]. Shoenfeld and Agmon-Levin's 2011 conceptualization synthesized these phenomena under a single pathophysiological framework, subsequently termed Shoenfeld's syndrome or human adjuvant-related syndrome [1, 11]. This nomenclatural evolution reflects ongoing scientific discourse regarding the boundaries of the syndrome and the specificity of its diagnostic criteria within contemporary autoimmunology.

IMMUNOPATHOGENIC MECHANISMS

Understanding the molecular and cellular cascades underlying adjuvant-induced autoimmunity requires examination of complex immunological interactions. Adjuvants can inadvertently trigger pathological immune responses in genetically susceptible individuals [12]. The progression from beneficial immune stimulation to aberrant autoimmunity involves multiple interconnected pathways, including innate immune dysregulation, adaptive immune activation, and chronic inflammatory processes [13]. These mechanisms operate synergistically, with genetic predisposition and environmental factors modulating individual susceptibility [14]. Elucidating these pathophysiological processes remains fundamental to understanding ASIA and developing targeted therapeutic interventions [15].

- **Adjuvant Immunology and Mechanisms of Action**

Immune responses are initiated by adjuvants through the activation of pattern recognition receptors, with Toll-like and NOD-like receptors serving as primary mediators that subsequently trigger inflammasome cascades and induce pro-inflammatory cytokine secretion [16]. This innate activation promotes dendritic cell maturation and migration to lymphoid tissues, enhancing their antigen presentation capacity. Subsequent amplification of cytokine and chemokine cascades recruits additional immune cells, perpetuating inflammatory responses. Critically, antigen-adjuvant complexes can form persistent deposits at injection sites, creating foci of chronic stimulation [17]. In susceptible individuals, these mechanisms may escape regulatory

control, culminating in sustained autoimmune activation rather than resolving protective immunity.

- **Breakdown of Immune Tolerance**

The disruption of immune tolerance represents a central pathogenic mechanism in ASIA. Molecular mimicry occurs when structural homology exists between adjuvant-associated epitopes and self-antigens, triggering cross-reactive immune responses [18]. Bystander activation amplifies this process, wherein inflammatory environments enable T-cells to recognize previously cryptic self-epitopes, facilitating epitope spreading [19]. Concurrently, regulatory T-cell populations exhibit numerical and functional deficiencies, compromising their immunosuppressive capacity [20]. B-cell tolerance checkpoints become compromised, permitting autoreactive B-cells to escape negative selection and produce pathogenic autoantibodies, including antinuclear antibodies and anti-extractable nuclear antigens [21]. These interconnected mechanisms [22,23] collectively destroy self-tolerance, leading to sustained autoimmune inflammation in genetically susceptible individuals.

- **Genetic Susceptibility Factors**

Individual vulnerability to adjuvant-triggered reactions stems from multiple genetic factors: specific HLA allelic variations can enhance the presentation of autoantigens, while polymorphisms in cytokine genes (particularly IL-1β and TNF-α) and xenobiotic enzyme genes modify both immunological reactivity and toxin metabolism pathways [22,23]. Epigenetic modifications (e.g., DNA methylation, histone modifications) triggered by adjuvants can silence regulatory genes, promoting chronic inflammation [24]. Fundamentally, individual risk arises from a dynamic gene-environment interplay: a carrier of risk alleles may remain asymptomatic without an environmental trigger, whereas others may develop autoimmunity after minor exposures [25]. These genetic factors form a complex network underpinning predisposition to immune dysregulation following adjuvant exposure.

- **Chronic Inflammatory Pathways**

Sustained inflammatory processes characterizing ASIA depend on macrophage phenotypic shifts that perpetuate inflammatory activity within anatomical regions harboring deposited adjuvant materials [26]. This polarization dynamics underpins granuloma formation, as exemplified by macrophagic myofasciitis pathophysiology, where macrophages laden with adjuvants create distinctive granulomatous lesions [27]. These activated macrophages release pro-inflammatory mediators, including IL-1β, IL-

6, and TNF-α, which enter systemic circulation and potentially cross the blood-brain barrier [28]. Evidence suggests these cytokines facilitate neuroimmune crosstalk, activating microglia and astrocytes, thereby contributing to the neurological symptoms, including chronic fatigue, cognitive impairment, and myalgia, reported in susceptible individuals [29,30].

SUBSTANCES IMPLICATED IN ASIA SYNDROME

ASIA syndrome encompasses diverse adjuvant exposures that can trigger autoimmune manifestations in genetically susceptible individuals [31]. Aluminum hydroxide and phosphate, widely used in vaccines, promote dendritic cell activation and prolonged cytokine release, potentially driving autoimmunity [32]. Squalene, used in oil-in-water emulsions like MF59, enhances antigen presentation but may cross-react with self-antigens in predisposed hosts [33]. Silicone implants have been linked to systemic inflammation and autoantibody production [34]. Although generally safe, these substances can breach immune tolerance in vulnerable individuals, manifesting as fatigue, myalgia, or autoimmune phenomena. Genetic predisposition modulates individual responses to these adjuvants, influencing disease onset and severity.

- **Aluminum-Based Adjuvants**

Various aluminum formulations, including hydroxide, phosphate, and alum compounds, demonstrate unique pharmacokinetic behaviors. Their nanoparticulate architecture enables extended retention within injection site tissues, followed by gradual migration to lymphoid structures, neural tissue, and skeletal elements [35]. Biodistribution studies reveal dose-dependent accumulation patterns, with elimination half-lives extending from months to years, depending on formulation crystallinity [36]. Cumulative aluminum burden from multiple vaccinations may exceed theoretical safety thresholds in vulnerable populations [37]. Mechanistically, aluminum adjuvants activate the NLRP3 inflammasome, stimulate dendritic cell maturation, and promote Th2-polarized immune responses through danger-associated molecular pattern recognition [38]. Individual variations in aluminum metabolism significantly influence susceptibility to adjuvant-induced autoimmune manifestations.

- **Silicone and Biomaterials**

Degradation of silicone breast prostheses generates particulate material capable of lymphatic dissemination to proximal lymph nodes, hepatic tissue, and splenic parenchyma, where these particles incite granulomatous inflammatory responses

accompanied by autoantibody synthesis [39]. Polydimethylsiloxane fragments function as persistent adjuvants, perpetuating immune dysregulation through macrophage activation and cytokine release [40]. Polypropylene meshes employed in hernia repair have similarly been implicated in ASIA syndrome, inducing chronic foreign body reactions with systemic inflammatory sequelae [41]. Additional biomaterials, including polyurethane-coated devices, metallic orthopedic implants, and acrylic bone cement, exhibit immunostimulatory capacity, particularly in genetically predisposed individuals harboring specific HLA haplotypes [42]. Understanding biomaterial-host interactions remains essential for preventing implant-associated autoimmune phenomena.

- **Infectious Agents as Adjuvants**

Viral and bacterial pathogen-associated molecular patterns function as endogenous adjuvants, activating innate immune receptors and precipitating autoimmune sequelae through molecular mimicry and bystander activation [43]. Post-infectious autoimmune disorders demonstrate phenomenological overlap with ASIA syndrome, sharing common immunopathological mechanisms [44]. SARS-CoV-2 infection emerges as a potent ASIA trigger, with spike protein epitopes cross-reacting with self-antigens and inducing persistent immune dysregulation manifesting as post-acute sequelae [8]. Epstein-Barr virus and cytomegalovirus reactivation following adjuvant exposure may synergistically amplify autoimmune responses in susceptible hosts [45]. Distinguishing infectious from adjuvant-mediated autoimmunity requires comprehensive immunological phenotyping.

- **Novel and Emerging Adjuvants**

Next-generation vaccine adjuvants, such as AS01 (MPL + QS-21), AS03 (α-tocopherol), MF59, and CpG oligonucleotides, demonstrate enhanced immunogenicity through Toll-like receptor engagement, yet pose theoretical risks for ASIA syndrome given their potent immune-activating properties [46]. Hyaluronic acid dermal fillers and polymethylmethacrylate-based cosmetic biomaterials can trigger granulomatous reactions with systemic autoimmune manifestations in susceptible individuals [47]. Occupational silica exposure induces adjuvant-like effects, precipitating scleroderma and lupus-like syndromes [48]. Engineered nanomaterials, including carbon nanotubes and metallic nanoparticles, exhibit intrinsic immunostimulatory capacity through oxidative stress pathways and inflammasome activation [49]. While beneficial for immunization or aesthetics, these agents may inadvertently fuel ASIA-like phenotypes in susceptible

individuals. Rigorous long-term immunotoxicity profiling is essential as these technologies expand into everyday use.

CLINICAL MANIFESTATIONS AND PHENOTYPIC SPECTRUM

ASIA syndrome exhibits remarkable clinical heterogeneity, encompassing constitutional symptoms such as chronic fatigue, arthralgias, myalgias, and cognitive dysfunction, which typically emerge months to years after adjuvant exposure [50]. Neurological manifestations range from peripheral neuropathies to demyelinating disorders mimicking multiple sclerosis [51]. Dermatological features include chronic urticaria, alopecia, and photosensitivity, while sicca syndrome and Raynaud's phenomenon frequently occur [52]. Autoantibody profiles are highly variable, with anti-nuclear antibodies, anti-extractable nuclear antigens, and novel anti-adjuvant antibodies detected inconsistently [53]. Phenotypic expression correlates with the type of adjuvant, cumulative dose, genetic susceptibility, and individual immunological background, necessitating personalized diagnostic approaches that account for this protean clinical spectrum.

- **Core Clinical Features**

Principal clinical manifestations include systemic constitutional features—notably persistent exhaustion, low-grade fever, and nocturnal diaphoresis—which collectively indicate widespread immune system engagement [54]. Musculoskeletal manifestations frequently include arthralgia, myalgia, and varying patterns of arthritis that contribute to significant morbidity [55]. Neurological and cognitive disturbances are common, manifesting as peripheral neuropathy, cognitive dysfunction, and headaches [56]. Dermatological findings such as rashes, sicca symptoms, and other cutaneous manifestations further diversify the clinical phenotype [57]. These presentations underscore ASIA’s heterogeneity, and symptom severity often correlates poorly with autoantibody titers, complicating diagnostic certainty and emphasizing the importance of thorough clinical phenotyping.

- **Organ System Involvement**

Organ system involvement in ASIA syndrome extends beyond the musculoskeletal system. Pulmonary complications, particularly interstitial lung disease, can arise through inflammatory pathways triggered by persistent adjuvant presence [58]. Cardiovascular manifestations encompass pericarditis and small-vessel vasculitis, reflecting systemic immune dysregulation [59]. Gastrointestinal symptoms frequently

coexist with hepatic abnormalities, suggesting broader autoimmune cross-reactivity [60]. Endocrine dysfunction represents a critical yet underrecognized domain, with thyroid autoimmunity being particularly prevalent [61]. The heterogeneous nature of organ involvement underscores the syndrome's complexity, where adjuvant-triggered immune activation cascades into multi-system pathology through mechanisms such as molecular mimicry and epitope spreading.

- **Temporal Patterns and Disease Trajectory**

Symptom emergence following adjuvant exposure exhibits substantial temporal variability, with documented intervals ranging from 3 days to 5 years; epidemiological data suggest a median latency of approximately 17 months [11]. Macrophagic myofasciitis typically presents around seven months post-vaccination [62]. Acute presentation patterns predominantly emerge within one to seven weeks following exposure, whereas chronic manifestations develop insidiously over months to years [63]. Disease progression remains unpredictable, with approximately 20% of patients developing well-defined autoimmune conditions superimposed upon their initial constitutional symptoms [64]. Factors influencing severity include genetic predisposition—particularly HLA-DRB1 and PTPN22 polymorphisms—cumulative adjuvant burden, and a pre-existing autoimmune diathesis [65]. Symptom chronicity correlates with the duration of adjuvant persistence and individual immunogenetic profiles.

- **Overlap with Established Autoimmune Diseases**

ASIA syndrome frequently demonstrates phenotypic overlap with established autoimmune disorders, complicating differential diagnosis [66]. Lupus-like manifestations occur in approximately 3.6% of cases, featuring malar rashes, serositis, and positive anti-dsDNA antibodies following adjuvant exposure [8]. Sjögren's syndrome represents the second most common overlap, affecting 9.8% of ASIA patients with sicca complex and anti-SSA positivity [67]. Undifferentiated connective tissue disease emerges as the predominant overlap pattern, while fibromyalgia symptomatology permeates nearly half of all presentations [68]. Evolution toward definitive autoimmune diagnoses constitutes a recognized minor criterion, with approximately 20% of patients progressing beyond their initial ASIA manifestations [69]. Differential diagnosis necessitates careful temporal correlation with adjuvant exposure, histopathological confirmation, and documented symptom amelioration following adjuvant removal.

DIAGNOSTIC APPROACHES AND CRITERIA

The diagnosis of ASIA syndrome relies on the criteria established by Shoenfeld and Agmon-Levin in 2011, which require either two major criteria or one major criterion plus two minor criteria [1]. Alijotas-Reig proposed modified criteria in 2015 emphasizing objective measures, although formal validation remains pending [5]. Diagnosis necessitates a comprehensive clinical assessment, including detailed documentation of adjuvant exposure, temporal correlation with symptom onset, and characteristic clinical manifestations. Laboratory investigations encompass autoantibody profiling and inflammatory markers, while histopathological examination may reveal macrophagic myofasciitis or granulomatous patterns.

- **Evolution of Diagnostic Criteria**

The diagnostic criteria for ASIA syndrome, first established by Shoenfeld and Agmon-Levin in 2011, include major clinical and exposure features for classification. The original 2011 framework required two major or one major plus two minor criteria for diagnosis [1]. Alijotas-Reig subsequently proposed modified criteria emphasizing objective measures, though formal validation remains pending [5]. Comparative analyses reveal high sensitivity but suboptimal specificity in current criteria, generating ongoing controversy regarding diagnostic thresholds [70]. Recent proposals advocate incorporating markers of dysautonomia and findings of small fiber neuropathy to enhance discriminatory capacity [8].

- **Clinical Diagnostic Assessment**

Clinical assessment of ASIA syndrome necessitates meticulous documentation of adjuvant exposure. Physical examination often reveals characteristic findings such as myalgia, arthralgia, chronic fatigue, and autoimmune manifestations. A clear temporal correlation between exposure and symptom onset is critical for diagnosis, with symptoms potentially delayed by months or years [13]. Clinical improvement following adjuvant removal or explant surgery provides fundamental diagnostic validation, although response variability exists [71].

- **Laboratory Investigations**

Laboratory investigations in ASIA syndrome demonstrate heterogeneous serological profiles. Antinuclear antibodies represent the predominant autoantibody finding, frequently accompanied by positive anti-extractable nuclear antigen specificities [72]. Genetic susceptibility assessment through HLA-DRB1 and HLA-DQ2 haplotyping provides prognostic insights, although inflammatory markers such as erythrocyte

sedimentation rate, C-reactive protein, and interleukin-6 often yield inconsistent elevations [73]. Anti-phospholipid antibodies occasionally manifest in specific clinical phenotypes [74]. Diagnostic challenges include variable sensitivity, inter-laboratory standardization issues, and differentiating transient from persistent antibody responses, necessitating comprehensive clinical-serological correlation.

- **Histopathological Findings**

Macrophagic myofasciitis constitutes the pathognomonic histological hallmark, exhibiting focal epimysial, perimysial, and endomysial infiltration by cohesive basophilic macrophages containing aluminum hydroxide nanocrystals, demonstrable via Periodic Acid-Schiff staining and Morin fluorescence [75]. Immunohistochemical characterization reveals intense CD68 expression with accompanying lymphocytic populations [76]. Granulomatous inflammation patterns manifest with foreign-body giant cells, histiocytic aggregation, and variable fibrosis [32]. Deltoid muscle biopsy represents the optimal diagnostic approach, revealing tissue architecture disruption through perifascicular macrophage accumulation without significant myofiber necrosis. Electron microscopy demonstrates characteristic spiculated aluminum-containing inclusions within macrophage cytoplasm [77].

- **Imaging Modalities**

Advanced imaging is pivotal for evaluating ASIA syndrome. Magnetic resonance imaging with T2-weighted and STIR sequences precisely delineates muscle edema, atrophy, and spinal cord lesions, providing crucial neurological assessment [78]. For detecting subclinical inflammation, positron emission tomography using 18F-FDG tracer effectively maps metabolically active inflammatory foci [79]. Furthermore, high-resolution ultrasonography is indispensable for real-time assessment of silicone breast implant integrity and the surrounding capsular tissue, identifying ruptures and peri-implant fluid collections [66].

EPIDEMIOLOGICAL CONSIDERATIONS

The epidemiological assessment of ASIA syndrome remains challenging due to underreporting and diagnostic heterogeneity across populations. Prevalence estimates vary substantially, reflecting diverse adjuvant exposures and genetic susceptibilities. Women demonstrate higher susceptibility, suggesting hormonal influences on autoimmune triggering mechanisms. Long latency periods between adjuvant exposure

and symptom manifestation complicate causal attribution, necessitating robust registry systems for accurate incidence characterization [80].

- **Incidence and Prevalence Estimates**

Population-based occurrence rates for ASIA remain largely undefined, with heterogeneous epidemiological data across geographic regions. Diagnostic recognition challenges persist due to phenotypic variability and overlapping autoimmune manifestations. Substantial underreporting occurs secondary to inadequate clinician awareness and the absence of standardized diagnostic criteria. Regional variations reflect differential adjuvant exposure patterns, genetic susceptibilities, and disparities in healthcare infrastructure [81]. Enhanced surveillance mechanisms and international registry initiatives are imperative for accurate prevalence quantification.

- **Risk Factors and Vulnerable Populations**

Female predominance characterizes ASIA syndrome manifestations, paralleling broader autoimmune disease patterns attributed to sex hormone-mediated immunological amplification [82]. Genetic susceptibility markers, particularly HLA-DRB1 and PTPN22 polymorphisms, confer heightened vulnerability to adjuvant-induced autoimmunity [83]. Pre-existing autoimmune conditions substantially elevate the risk of ASIA syndrome through mechanisms of immune dysregulation [84]. Occupational exposures, including healthcare workers encountering repeated vaccine adjuvants and individuals with silicone or metallic implants, represent epidemiologically significant risk strata [85]. Age-dependent immune senescence modulates susceptibility patterns across demographic cohorts.

- **Adjuvant Exposure Patterns**

Cumulative aluminum burden demonstrates variable latency periods, averaging 16.8 months between initial exposure and clinical manifestation onset [86]. Contemporary vaccination schedules necessitate systematic evaluation of total adjuvant load, particularly during early developmental periods when immune surveillance mechanisms remain immature. Temporal clustering of multiple adjuvant-containing immunizations may potentiate immunological hyperactivation in susceptible individuals. Definitive dose-response relationships remain elusive, with clinical expression appearing more contingent upon genetic predisposition than absolute adjuvant quantity [87]. Investigation of exposure frequency patterns reveals heterogeneous individual susceptibility thresholds, complicating standardized risk stratification.

THERAPEUTIC MANAGEMENT STRATEGIES OF ASIA SYNDROME

Therapeutic interventions for ASIA syndrome remain predominantly empirical, reflecting the substantial heterogeneity in clinical presentations and the limited availability of standardized management protocols [88]. Primary treatment emphasizes complete adjuvant removal when feasible, which has demonstrated symptomatic resolution in appropriately selected cases. Immunomodulatory regimens incorporating corticosteroids, conventional disease-modifying agents, and emerging biologic therapies represent cornerstone pharmacological approaches for managing persistent inflammatory manifestations [89]. Treatment plans require individualization based on disease severity and comorbidities for optimal outcomes. Multidisciplinary coordination, integrating rheumatological expertise with surgical consultation, optimizes outcomes, particularly in scenarios involving implanted foreign materials requiring explantation procedures.

Adjuvant Source Removal

Explantation of silicone breast implants using en bloc capsulectomy techniques has demonstrated symptomatic improvement in approximately 50-69% of cases, with fatigue, arthralgia, and myalgia showing preferential response patterns [90]. Biomaterial removal, including metallic orthopedic hardware and dental implants, represents a definitive intervention when conservative immunomodulation proves inadequate [91]. Evidence supporting post-explantation symptomatic amelioration remains heterogeneous, with complete capsular excision demonstrating superior outcomes compared to simple implant removal [92]. Optimal intervention timing favors earlier removal following symptom onset, although individual patient trajectories demonstrate substantial variability in recovery kinetics and durability of therapeutic response.

- **Immunomodulatory and Anti-Inflammatory Therapies**

The management of ASIA syndrome's immune phenomena requires a tailored approach. Immunomodulatory and anti-inflammatory therapies include corticosteroid regimens, typically initiated with high-dose pulses followed by gradual tapering based on clinical response [93]. Disease-modifying antirheumatic drugs such as hydroxychloroquine and methotrexate provide immunosuppression [94]. Biologic agents targeting TNF, IL-6, and B cells have shown promise, alongside intravenous immunoglobulin therapy [95]. Emerging targeted immunotherapies are under investigation to enhance specificity and efficacy.

- **Symptomatic and Supportive Management**

Symptomatic and supportive management includes analgesics for pain control. Physical therapy and rehabilitation target musculoskeletal symptoms to restore function. Cognitive and neuropsychological support address memory and mood disturbances. Fatigue management protocols incorporate lifestyle modifications, energy conservation strategies, and pharmacologic interventions to improve quality of life [96].

- **Treatment Outcomes and Prognosis**

Treatment outcomes in ASIA syndrome are variable. Early immunomodulatory intervention often yields favorable responses, with some patients achieving complete resolution [97]. Prognosis is generally better in cases with prompt adjuvant removal. Predicting individual responses remains challenging, although specific autoantibody profiles may be informative [98]. Serial clinical evaluation and monitoring of inflammatory markers are crucial for assessing disease activity and guiding therapy.

CONTROVERSIAL ASPECTS AND SCIENTIFIC DEBATE IN ASIA SYNDROME

The nosological validity of ASIA syndrome remains contested, with proponents arguing for its recognition as a distinct immunological entity, while critics highlight diagnostic imprecision and potential overlap with functional somatic syndromes. Discussions on vaccine safety necessitate nuanced risk-benefit analyses, balancing population-level epidemiological data against individual susceptibility profiles, thereby influencing public health policy and adjuvant selection [99]. Medico-legal ramifications encompass silicone implant litigation, vaccine injury compensation frameworks, and evidentiary challenges in establishing causality, requiring healthcare providers to navigate complex liability landscapes while maintaining evidence-based clinical decision-making [100].

FUTURE RESEARCH DIRECTIONS AND KNOWLEDGE GAPS IN ASIA SYNDROME

Mechanistic investigations employing single-cell transcriptomics and proteomics are essential for identifying prognostic biomarkers and elucidating targetable molecular pathways underlying ASIA syndrome [101]. Clinical research necessitates prospective cohort studies with standardized diagnostic protocols and randomized controlled trials evaluating therapeutic efficacy, alongside comprehensive natural history documentation [102]. Translational priorities include developing novel adjuvant formulations with

improved safety profiles, creating personalized risk stratification algorithms, and refining autoimmune disease nosology [103]. Regulatory frameworks must incorporate enhanced post-market surveillance, standardized adverse event reporting, and evidence-based guidelines integrating ASIA syndrome considerations into medical device evaluation processes.

CONCLUSION

ASIA syndrome represents a valuable conceptual framework linking adjuvant exposure to autoimmune manifestations, advancing understanding of immune dysregulation mechanisms despite ongoing nosological debates. Its clinical utility is evident in identifying susceptible populations and guiding explantation decisions, although diagnostic specificity requires further refinement. The syndrome's recognition has catalyzed enhanced vaccine adjuvant safety protocols and assessments of biomaterial biocompatibility. Future directions necessitate prospective cohort studies, advanced immunophenotyping, and standardized diagnostic criteria to validate its clinical significance while balancing individual patient care with population-level public health imperatives.

Conflict of Interest: The authors declare that they have no conflict of interest related to the publication of this manuscript.

REFERENCES

1. Shoenfeld Y, Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4-8.
2. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1-16.
3. Caldarelli M, Rio P, Giambra V, Gasbarrini A, Gambassi G, Cianci R. ASIA Syndrome: State-of-the-Art and Future Perspectives. Vaccines (Basel). 2024;12(10):1183.
4. Juan Esteban OG, María Gabriela LA, María Camila AG, Edgar Felipe MS, María Camila AM, et al. Clinical Characteristics of ASIA Syndrome in Patients with

Silicone Breast Implants: A Scoping Review. World J Plast Surg. 2025;14(2):11-20.

5. Alijotas-Reig J. Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria. Lupus. 2015;24(10):1012-8.
6. Jara LJ, Medina G, Gómez-Bañuelos E, Saavedra MA, Vera-Lastra O. Still's disease, lupus-like syndrome, and silicone breast implants. A case of 'ASIA' (Shoenfeld's syndrome). Lupus. 2012;21(2):140-5.
7. Seida I, Seida R, Elsalti A, Mahroum N. Vaccines and Autoimmunity-From Side Effects to ASIA Syndrome. Medicina (Kaunas). 2023;59(2):364.
8. Cohen Tervaert JW, Martinez-Lavin M, Jara LJ, Halpert G, Watad A, Amital H, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023. Autoimmun Rev. 2023;22(5):103287.
9. Hotopf M, David AS, Hull L, Nikalaou V, Unwin C, Wessely S. Gulf war illness--better, worse, or just the same? A cohort study. BMJ. 2003;327(7428):1370.
10. Yousfi J, Oumlil S, Essaadouni L. Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) after Silicone Breast Implants. Eur J Case Rep Intern Med. 2025;12(2):005048.
11. Watad A, Quaresma M, Brown S, Cohen Tervaert JW, Rodríguez-Pint I, Cervera R, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome) - An update. Lupus. 2017;26(7):675-681.
12. Di Pasquale A, Preiss S, Tavares Da Silva F, Garçon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015;3(2):320-43.
13. Rajchenberg D, Wegerhoff N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) from 2011 to 2024: A comprehensive bibliometric review. Autoimmun Rev. 2024;23(12):103676.
14. Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P, Jara LJ, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol. 2013;9(4):361-73.
15. Watad A, Bragazzi NL, McGonagle D, Adawi M, Bridgewood C, Damiani G, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations

according to the adjuvant subtype: Insights from an analysis of 500 cases. Clin Immunol. 2019;203:1-8.

16. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122-6.
17. Li J, Ishaq M, Prudence M, Xi X, Hu T, Liu Q, Guo D. Single mutation at the amino acid position 627 of PB2 that leads to increased virulence of an H5N1 avian influenza virus during adaptation in mice can be compensated by multiple mutations at other sites of PB2. Virus Res. 2009;144(1-2):123-9.
18. Andrade LJO, de Oliveira GCM, de Oliveira LCM, Bittencourt AMV, Baumgarth Y, de Oliveira LM. Decoding the relationship between cow's milk proteins and development of type 1 diabetes mellitus. Arch Endocrinol Metab. 2024;68:e230248.
19. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2(2):85-95.
20. Hoyos-Bachiloglu R, Chou J. Autoimmunity and immunodeficiency. Curr Opin Rheumatol. 2020;32(2):168-174.
21. Meffre E, O'Connor KC. Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev. 2019;292(1):90-101.
22. Borba V, Malkova A, Basantsova N, Halpert G, Andreoli L, Tincani A, Amital H, Shoenfeld Y. Classical Examples of the Concept of the ASIA Syndrome. Biomolecules. 2020;10(10):1436.
23. Ozato K, Tsujimura H, Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques. 2002;Suppl:66-8, 70, 72 passim.
24. Moss TJ, Wallrath LL. Connections between epigenetic gene silencing and human disease. Mutat Res. 2007;618(1-2):163-74.
25. Sakaguchi S, Tanaka S, Tanaka A, Ito Y, Maeda S, Sakaguchi N, et al. Thymus, innate immunity and autoimmune arthritis: interplay of gene and environment. FEBS Lett. 2011;585(23):3633-9.
26. Luo M, Zhao F, Cheng H, Su M, Wang Y. Macrophage polarization: an important role in inflammatory diseases. Front Immunol. 2024;15:1352946.

27. Kim H, Lim KY, Kang J, Park JW, Park SH. Macrophagic myofasciitis and subcutaneous pseudolymphoma caused by aluminium adjuvants. Sci Rep. 2020;10(1):11834.
28. Crépeaux G, Eidi H, David MO, Tzavara E, Giros B, Exley C, et al. Highly delayed systemic translocation of aluminum-based adjuvant in CD1 mice following intramuscular injections. J Inorg Biochem. 2015;152:199-205.
29. Müller L, Di Benedetto S. Neuroimmune crosstalk in chronic neuroinflammation: microglial interactions and immune modulation. Front Cell Neurosci. 2025;19:1575022.
30. Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9(1):42.
31. Ospina-Gómez JE, Ayala-Gutierrez MC, Amaya Muñoz MC, Cáceres Ramírez C, Monsalve-Suárez EF, Saaibi-Solano DL, et al. Adjuvant-Induced Autoimmune Syndrome: A Bibliometric Analysis. Cureus. 2024;16(7):e65184.
32. Colaris MJL, de Boer M, van der Hulst RR, Cohen Tervaert JW. Two hundreds cases of ASIA syndrome following silicone implants: a comparative study of 30 years and a review of current literature. Immunol Res. 2017;65(1):120-128.
33. Watad A, Sharif K, Shoenfeld Y. The ASIA syndrome: basic concepts. Mediterr J Rheumatol. 2017;28(2):64-69.
34. Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases". Clin Immunol. 2021;224:108665.
35. Angrand L, Gherardi RK, Crépeaux G. Regulatory limits of aluminium content of vaccines have not been set based on toxicological studies. Environ Toxicol Pharmacol. 2025;119:104812.
36. Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023;8(1):283.
37. Lyons-Weiler J, Ricketson R. Reconsideration of the immunotherapeutic pediatric safe dose levels of aluminum. J Trace Elem Med Biol. 2018;48:67-73.
38. Zhu X, Hao W, Liu Z, Song Y, Hao C, Wu S, et al. Aluminum induces neuroinflammation via P2X7 receptor activating NLRP3 inflammasome pathway. Ecotoxicol Environ Saf. 2023;249:114373.

39. Cohen Tervaert JW, Kappel RM. Silicone implant incompatibility syndrome (SIIS): a frequent cause of ASIA (Shoenfeld's syndrome). Immunol Res. 2013;56(2-3):293-8.
40. Roberts J, Kearns M, Ismail Y, Scott J. Leakage of ruptured silicone breast implants through abdominal laparoscopic port sites: A rare complication following transabdominoplasty breast augmentation. JPRAS Open. 2021;30:146-152.
41. Gielen MJCAM, van Rest KLC, Bouvy ND, van Koeveringe GA, Kowalik CR, Roovers JPWR, et al. Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA Syndrome) After Polypropylene Mesh Implantation - Protocol of a Pilot Study for Diagnostics and Treatment. J Abdom Wall Surg. 2025;4:14266.
42. Kaplan SS. Biomaterial-host interactions: consequences, determined by implant retrieval analysis. Med Prog Technol. 1994;20(3-4):209-30.
43. Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, et al. Molecular mimicry and autoimmunity. J Autoimmun. 2018;95:100-123.
44. Williams KA, Swedo SE. Post-infectious autoimmune disorders: Sydenham's chorea, PANDAS and beyond. Brain Res. 2015;1617:144-54.
45. Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses. 2019;11(8):762.
46. Garçon N, Di Pasquale A. From discovery to licensure, the Adjuvant System story. Hum Vaccin Immunother. 2017;13(1):19-33.
47. Hooks JST, Yang B, Maestas DR Jr, Andorko JI, Ruta A, Mejias JC, et al. Innate and Adaptive Immune Responses to Clinical Hyaluronic Acid Fillers. J Cosmet Dermatol. 2025;24(7):e70292.
48. Pollard KM. Silica, Silicosis, and Autoimmunity. Front Immunol. 2016;7:97.
49. Kyriakides TR, Raj A, Tseng TH, Xiao H, Nguyen R, Mohammed FS, et al. Biocompatibility of nanomaterials and their immunological properties. Biomed Mater. 2021;16(4):10.1088/1748-605X/abe5fa.
50. Borba V, Hernández AL, Watad A, Shoenfeld Y. (2025). ASIA Syndrome. In Autoimmune Disease Diagnosis: Systemic and Organ-specific Diseases (pp. 323-327). Cham: Springer Nature Switzerland.

51. Goren I, Segal G, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvant (ASIA) evolution after silicone implants. Who is at risk? Clin Rheumatol. 2015;34(10):1661-6.
52. Knapik M, Owczarczyk-Saczonek A, Jaśkiewicz Ł, Kuna J, Chmielewski G, Krajewska-Włodarczyk M. Systemic Lupus Erythematosus (SLE) Induced by ASIA Syndrome After the Aesthetic Medicine Procedures-A Case Report. J Clin Med. 2024;14(1):119.
53. Shoenfeld Y, Ryabkova VA, Scheibenbogen C, Brinth L, Martinez-Lavin M, Ikeda S, et al. Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy. Clin Immunol. 2020;214:108384.
54. Gherardi RK, Crépeaux G, Authier FJ. Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system. Autoimmun Rev. 2019;18(7):691-705.
55. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18(13):1217-25.
56. Shadmani G, Simkins TJ, Assadsangabi R, Apperson M, Hacein-Bey L, Raslan O, Ivanovic V. Autoimmune diseases of the brain, imaging and clinical review. Neuroradiol J. 2022;35(2):152-169.
57. Del Giacco SR, Firinu D, Piludu G, Settembrini AM, Tulli M, Pirari P, et al. Raynaud's Phenomenon and Scleroderma Associated with Silicone Gel Breast Implants: An Example of Asia Syndrome. Eur J Inflamm. 2012;10(2):233–238.
58. Nesher G, Soriano A, Shlomai G, Iadgarov Y, Shulimzon TR, Borella E, et al. Severe ASIA syndrome associated with lymph node, thoracic, and pulmonary silicone infiltration following breast implant rupture: experience with four cases. Lupus. 2015;24(4-5):463-8.
59. Szappanos Á, Hajas Á, Hartyánszky I Jr, Kádár K, Kuthi L, Hartyánszky I, et al. Severe cardiovascular manifestation of ASIA syndrome triggered by silicone breast implants. Rheumatology (Oxford). 2025;64(3):1550-1552.
60. Posso-Osorio I, Méndez-Rayo T, Jimenez CA, Escobar D, Sepúlveda M, Navarro EP, et al. Hepatic infiltration by silicone in a patient With ASIA syndrome. Hepatology. 2018;67(1):444-445.

61. Bragazzi NL, Hejly A, Watad A, Adawi M, Amital H, Shoenfeld Y. ASIA syndrome and endocrine autoimmune disorders. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101412.
62. Masson JD, Badran G, Gherardi RK, Authier FJ, Crépeaux G. Widespread Myalgia and Chronic Fatigue: Phagocytes from Macrophagic Myofasciitis Patients Exposed to Aluminum Oxyhydroxide-Adjuvanted Vaccine Exhibit Specific Inflammatory, Autophagic, and Mitochondrial Responses. Toxics. 2024;12(7):491.
63. Rodríguez-García FA, Servín-Rodríguez CE, Torres-Salazar QL. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): A case of systemic symptoms following breast implants and vaccinations. Int J Surg Case Rep. 2024;124:110497.
64. Cojocaru M, Cojocaru IM, Silosi I. Multiple autoimmune syndrome. Maedica (Bucur). 2010;5(2):132-4.
65. Tizaoui K, Shin JI, Jeong GH, Yang JW, Park S, Kim JH, Hwang SY, Park SJ, Koyanagi A, Smith L. Genetic Polymorphism of PTPN22 in Autoimmune Diseases: A Comprehensive Review. Medicina (Kaunas). 2022;58(8):1034.
66. Kodzhaahmed LM, Korudova E, Batalov K, Petrova D, Batalov Z. Adjuvant-induced autoimmune syndrome (ASIA syndrome) and the role of sonography in its diagnosis: a case-based review. Rheumatol Int. 2025;45(10):246.
67. Seida I, Alrais M, Seida R, Alwani A, Kiyak Z, Elsalti A, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications. Clin Exp Immunol. 2023;213(1):87-101.
68. Mettler J, Ming-Azevedo P, Hügle T. Fibromyalgia with concomitant immune-mediated rheumatic diseases: an evaluation of clinical characteristics, diagnostic criteria and multimodal treatment outcomes. Adv Rheumatol. 2025;65(1):27.
69. Alijotas-Reig J, Esteve-Valverde E, Gil-Aliberas N, Garcia-Gimenez V. Autoimmune/inflammatory syndrome induced by adjuvants-ASIA-related to biomaterials: analysis of 45 cases and comprehensive review of the literature. Immunol Res. 2018;66(1):120-140.
70. Zhukova N, Orlova R, Malkova A, Kaledina E, Demchenkova A, Percik R, et al. The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy. Immunol Res. 2022;70(6):765-774.

71. Spoor J, Mureau MAM, Tissier RLM, Hommes J, Rakhorst H, de Boer M, et al. Breast implant illness after reconstruction with silicone breast implants. J Natl Cancer Inst. 2025;117(8):1717-1728.
72. Banhuk FW, Pahim BC, Jorge AS, Menolli RA. Relationships among Antibodies against Extractable Nuclear Antigens, Antinuclear Antibodies, and Autoimmune Diseases in a Brazilian Public Hospital. Autoimmune Dis. 2018;2018:9856910.
73. Caravantes-Cortes MI, Roldan-Valadez E, Zwojewski-Martinez RD, Salazar-Ruiz SY, Carballo-Zarate AA. Breast Prosthesis Syndrome: Pathophysiology and Management Algorithm. Aesthetic Plast Surg. 2020;44(5):1423-1437.
74. Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus. 2012;21(7):711-4.
75. Dias R, Faria R, Ribeiro D, Vasconcelos C. Macrophagic myofasciitis: an atypical presentation for a rare disease with a challenging approach. Reumatologia. 2020;58(3):167-172.
76. Ngo DQ, Le ST, Phan KHP, Doan TTP, Nguyen LNK, Dang MH, et al. Immunohistochemical expression in idiopathic inflammatory myopathies at a single center in Vietnam. J Pathol Transl Med. 2024;58(4):174-181.
77. Kalil RK, Monteiro A Jr, Lima MI, Silveira EB, Foltran FS, Martins CE, et al. Macrophagic myofasciitis in childhood: the role of scanning electron microscopy/energy-dispersive spectroscopy for diagnosis. Ultrastruct Pathol. 2007;31(1):45-50.
78. Almuqbel MM, Palmer NJ, Jenkins A, Keenan RJ, Melzer TR. Magnetic resonance imaging of breast implants: Optimizing tissue contrast. J Med Imaging Radiat Sci. 2023;54(1):9-15.
79. Bektaş M, Işık EG, Oğuz E, Kemik F, Abbasgholizadeh A, İnce B, et al. Utility of positron emission tomography as a new tool for muscle involvement in patients with idiopathic inflammatory myositis: a controlled study. Clin Exp Rheumatol. 2024;42(2):358-366.
80. Pellegrino P, Perrone V, Pozzi M, Carnovale C, Perrotta C, Clementi E, et al. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res. 2015;61(1-2):90-6.

81. Singh N, Picha GJ, Hardas B, Schumacher A, Murphy DK. Five-Year Safety Data for More than 55,000 Subjects following Breast Implantation: Comparison of Rare Adverse Event Rates with Silicone Implants versus National Norms and Saline Implants. Plast Reconstr Surg. 2017;140(4):666-679.
82. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600-9.
83. Steiner S, Becker SC, Hartwig J, Sotzny F, Lorenz S, Bauer S, et al. Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset. Front Immunol. 2020;11:578.
84. Malkova AM, Shoenfeld Y. Autoimmune autonomic nervous system imbalance and conditions: Chronic fatigue syndrome, fibromyalgia, silicone breast implants, COVID and post-COVID syndrome, sick building syndrome, post-orthostatic tachycardia syndrome, autoimmune diseases and autoimmune/inflammatory syndrome induced by adjuvants. Autoimmun Rev. 2023 Jan;22(1):103230.
85. Radenska-Lopovok SG, Kolesnikova AO, Egorova ON, Severinova MV, Musatov ID. Panniculitis as a manifestation of metal-associated autoimmune/inflammatory syndrome induced by adjuvants: a case-based review. Rheumatol Int. 2023;43(8):1547-1553.
86. Ashkenazi S. Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination. Isr Med Assoc J. 2023;25(2):161-162.
87. Lyons-Weiler J, McFarland G, La Joie E. Impact of catch-up vaccination on aluminum exposure due to new laws and post social distancing. J Trace Elem Med Biol. 2020;62:126649.
88. Puerta Sarmiento GE, Modragón I, Echeverri A, Sua LF, Bonilla-Abadía F, Aguirre-Valencia D. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA), medical treatment of severe systemic compromise: case report. Colomb Med (Cali). 2023;54(1):e5004625.
89. Montealegre G, Uribe R, Martínez-Ceballos MA, Rojas-Villarraga A. ASIA syndrome symptoms induced by gluteal biopolymer injections: Case-series and narrative review. Toxicol Rep. 2021;8:303-314.
90. Maijers MC, de Blok CJ, Niessen FB, van der Veldt AA, Ritt MJ, Winters HA, et al. Women with silicone breast implants and unexplained systemic symptoms: a descriptive cohort study. Neth J Med. 2013;71(10):534-40.

91. Schiff A, Jiries N, Goldsztein S, Schiff E, Ginsberg S. A possible association of orthopedic metal implants and ASIA syndrome. Rheumatology (Oxford). 2021;60(3):e95-e96.
92. Lieffering AS, Hommes JE, van der Hulst RRWJ, Rakhorst HA, Verheij RA, Mureau MAM, et al. Breast implant illness revisited: A cohort study of health symptoms in women with implant-based reconstruction. J Plast Reconstr Aesthet Surg. 2025;102:114-122.
93. Barman Kakil Ş, Pekdiker M, Akikol T. Anterior Uveitis Associated with ASIA Syndrome: A Distinct Clinical Entity? Ocul Immunol Inflamm. 2025;33(8):1712-1718.
94. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.
95. Chen CJ, Kao HY, Huang CH, Li CJ, Hung CH, Yong SB. New insight into the intravenous immunoglobulin treatment in Multisystem Inflammatory Syndrome in children and adults. Ital J Pediatr. 2024;50(1):18.
96. Trinh S, Le A, Gowani S, La-Beck NM. Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines. Asia Pac J Oncol Nurs. 2019;6(2):154-160.
97. Dotan A, Shoenfeld Y. Post-COVID syndrome: the aftershock of SARS-CoV-2. Int J Infect Dis. 2022;114:233-235.
98. Anzola LK, Ramirez S, Moreno S, Vargas C, Rojas S, Rivera JN. Somatostatin Receptor Scintigraphy in Autoimmune Syndrome Induced by Silicone Breast Implants: Pre- and Postexplantation Findings. J Clin Med. 2025;14(12):4141.
99. Rosenblum H, Shoenfeld Y, Amital H. The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. Infect Dis Clin North Am. 2011;25(4):851-63.
100. Hawkes D, Benhamu J, Sidwell T, Miles R, Dunlop RA. Revisiting adverse reactions to vaccines: A critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA). J Autoimmun. 2015;59:77-84.

101. Xiao H, Rosen A, Chhibbar P, Moise L, Das J. From bench to bedside via bytes: Multi-omic immunoprofiling and integration using machine learning and network approaches. Hum Vaccin Immunother. 2023;19(3):2282803.

102. Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123.

103. Baglaenko Y, Wagner C, Bhoj VG, Brodin P, Gershwin ME, Graham D, et al. Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders. Camb Prism Precis Med. 2023;1:e25.

This preprint was submitted under the following conditions:

- The authors declare that the necessary Terms of Free and Informed Consent of participants or patients in the research were obtained and are described in the manuscript, when applicable.
- The authors declare that the preparation of the manuscript followed the ethical norms of scientific communication.
- The authors declare that they are aware that they are solely responsible for the content of the preprint and that the deposit in SciELO Preprints does not mean any commitment on the part of SciELO, except its preservation and dissemination.
- The authors declare that the data, applications, and other content underlying the manuscript are referenced.
- The deposited manuscript is in PDF format.
- The authors declare that the research that originated the manuscript followed good ethical practices and that the necessary approvals from research ethics committees, when applicable, are described in the manuscript.
- The authors declare that once a manuscript is posted on the SciELO Preprints server, it can only be taken down on request to the SciELO Preprints server Editorial Secretariat, who will post a retraction notice in its place.
- The authors agree that the approved manuscript will be made available under a Creative Commons CC-BY license.
- The submitting author declares that the contributions of all authors and conflict of interest statement are included explicitly and in specific sections of the manuscript.
- The authors declare that the manuscript was not deposited and/or previously made available on another preprint server or published by a journal.
- If the manuscript is being reviewed or being prepared for publishing but not yet published by a journal, the authors declare that they have received authorization from the journal to make this deposit.
- The submitting author declares that all authors of the manuscript agree with the submission to SciELO Preprints.